SEC Form 4 · accession 0001562180-18-002995
PROGENICS PHARMACEUTICALS INC · PGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Jean Ferrante
Director
Period of report
Jun 13, 2018
Accepted (ET)
Jun 14, 2018 · 2:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000835887
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $8.99 | Jun 13, 2018 | A | 25,000 | A | Jun 13, 2018 | Jun 13, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1This stock option becomes exercisable immediately on the date of grant.